Skip to content

Category: Conversation

Optimizing Dosing in Oncology Drug Development Q & A

  Maximizing Benefit and Improving Tolerability for Patients Through Dose Optimization Virtual Event Questions and Answers   Friends of Cancer Research (Friends) continues to be committed to improving clinical trial design and drug development to support patients. In September 2021, Friends hosted an event called Beyond Breakthrough: Optimizing the Breakthrough Therapy Designation that highlighted ongoing…

Real-World Evidence Roundtable

Friends of Cancer Research (Friends) convened a roundtable meeting on February 6, 2019, to identify key challenges and next steps to further characterize how real-world evidence (RWE) can fill evidence gaps about the performance of approved agents used in the real-world setting, including in populations that may not have been included in initial clinical trials.…

Designing the Future of Cell Therapies

“Patients are waiting. These therapies are potentially curative. They’re important for the field.” – Ellen Sigal On May 17, 2019, Friends of Cancer Research (Friends) and the Parker Institute for Cancer Immunotherapy (PICI) held a public meeting on “Designing the Future of Cell Therapies” to explore forward-looking opportunities in the cell therapy field. The meeting…

22nd Annual Cancer Leadership Awards Reception

This year’s awardees at the 22nd Annual Cancer Leadership Awards Reception From L-R: Dr. Anthony Fauci, Dr. Richard Klausner September 21, 2018 The Hay-Adams 800 16th St NW, Washington, DC 20006 On September 21, 2018, Friends of Cancer Research (Friends) hosted the 22nd Annual Cancer Leadership Awards Reception. The yearly event brings together leaders in…

A Blueprint for Breakthrough: Research and Reimbursement in the Age of Precision Medicine

Next-generation sequencing (NGS) is becoming a commonly used tool in cancer treatment. Transparency regarding the clinical performance and utility of different NGS-based tests available will aid in clinical decision-making and facilitate improvements in patient care.  The 7th Annual Blueprint for Breakthrough Forum, held by Friends of Cancer Research (Friends) and Alexandria Real Estate Equities, Inc.,…

A Plea to Make Cancer Clinical Trials More Patient Friendly

Jim Omel is a myeloma patient and a cancer research advocate. He spoke at the 2017 Friends of Cancer Research Annual Meeting and was an author of the panel 2 whitepaper, Data Generation to Support Cross-Labeling of Indications for Combination Products. Below are his abridged remarks from the meeting. To view his remarks in full,…

The Magic of Summer at Camp Fantastic

With summer now behind us, we thought it would be a good time to reflect on one of the special experiences our science policy analyst, Diana Merino, had over the summer… This summer, for the second year in a row, I got to spend a week volunteering at Camp Fantastic, a camp that provides an…

Keeping Patients at the Forefront of Our Work

I was 18 when my life was turned upside down by cancer. My mother was diagnosed with a highly aggressive malignancy after a colonoscopy due to a flair-up of Crohn’s disease. She spent the next two months in the hospital after the surgery to remove the malignancy left her near death with adhesions, requiring a…

Tough as Hell – A Breast Cancer Fighter Tells Her Story

In November 2014, assistant professor, Jenna Kieckhaefer, was diagnosed with breast cancer. She was only 28 years old at the time.     The concept of having breast cancer first came to Jenna’s attention when she was working on her PhD. She went for an annual visit and was informed she had lumpy breasts. While…

David Baltimore Talks Cancer, Research, and How Things Have Changed Since He Was in High School

David Baltimore is a world-renowned biologist who in 1975 won the Nobel Prize in physiology or medicine along with Howard Temin and Renato Dulbecco “for their discoveries concerning the interaction between tumor viruses and the genetic material of the cell.” We had the chance to sit down and discuss science, cancer research, and more with…